Prevention of nickel subsulfide carcinogenesis by local administration of Mycobacterium bovis antigen in male F344/NCr rats. 1991

K S Kasprzak, and J M Ward
Laboratory of Comparative Carcinogenesis, National Cancer Institute-FCRDC, Frederick, MD 21702.

This study was designed to determine the effect of local inflammation on nickel subsulfide (Ni3S2) carcinogenesis. Male F344/NCr rats, 6-week-old, 20 rats/group, received a single i.m. injection of 2.5 mg of Ni3S2 alone or 2.5 mg of Ni3S2 mixed with either 0.5 mg of Mycobacterium bovis lyophilized cell walls (MB), 1 mg cortisol (CORT), or 1 mg indomethacin (IND). Two more groups of rats received i.m. Ni3S2 alone, as above, followed by a single s.c. dose of either 1 mg MB or 2 mg IND. The i.m. injections were made into the thigh muscles of both hind limbs; the s.c. injections were made at the neck area. The experiment was terminated at 71 weeks. The final yields of injection site sarcomas were 85% in the Ni3S2, 85% in the Ni3S2 + CORT, and 80% in the Ni3S2 + IND group. Only one injection site tumor (5%) was found in rats given i.m. Ni3S2 + MB. In contrast, the s.c. MB injection enhanced muscular carcinogenicity of Ni3S2 by shortening the latency and increasing the yield of tumors to 100% at week 39 (P less than 0.04 vs. Ni3S2 alone). The s.c. treatment with IND gave similar, though statistically nonsignificant results; 100% tumor yield was reached at week 42 (P less than 0.18 vs. Ni3S2 alone). Although local treatment with CORT or IND had no significant effect on the final tumor incidence by Ni3S2, it shortened the latency of tumors to 17 weeks compared with 23 weeks for Ni3S2 alone. MB, CORT, IND, or the injection vehicle (water) alone did not produce tumors. Local MB treatment had no significant effect on the retention of Ni3S2 at the injection site. The prevention of the Ni3S2 tumors by local MB might result from localization of numerous natural killer cells and macrophages and formation of giant cells observed at the injection site of Ni3S2, 1-14 days post injection. These cells could immobilize the carcinogen and destroy Ni3S2-transformed cells.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008297 Male Males
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009532 Nickel A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor

Related Publications

K S Kasprzak, and J M Ward
May 2023, Journal of applied toxicology : JAT,
K S Kasprzak, and J M Ward
November 1988, Toxicology,
K S Kasprzak, and J M Ward
April 2011, Biomedical and environmental sciences : BES,
K S Kasprzak, and J M Ward
November 1995, Toxicology,
K S Kasprzak, and J M Ward
July 1996, National Toxicology Program technical report series,
K S Kasprzak, and J M Ward
January 1983, Basic life sciences,
K S Kasprzak, and J M Ward
September 1994, Environmental health perspectives,
K S Kasprzak, and J M Ward
January 1977, Advances in experimental medicine and biology,
Copied contents to your clipboard!